AbbVie Acquires Gilgamesh Pharmaceuticals' Bretisilocin for Major Depressive Disorder

Why This Matters: This acquisition signifies a major investment in psychedelic-based therapies for mental health, potentially offering new hope for patients who have not responded to traditional treatments. The shorter duration of psychoactive experience with Bretisilocin may address a key limitation of existing psychedelic agents.

AbbVie's move to acquire Gilgamesh's Bretisilocin program highlights the growing interest in psychedelic compounds as potential treatments for mental health disorders. Bretisilocin's unique mechanism of action, targeting the 5-HT2A receptor, has shown promise in early clinical trials.

The Phase 2a study demonstrated a robust antidepressant effect with a single dose, indicating the potential for rapid symptom relief. The drug was also well-tolerated, with no serious adverse events reported. This acquisition builds upon a previous collaboration between AbbVie and Gilgamesh, further solidifying their partnership in developing next-generation therapies for psychiatric disorders.

Gilgamesh Pharma Inc., the spun-off entity, will continue to advance other programs, including blixeprodil (GM-1020), an oral NMDA receptor antagonist, and a cardio-safe ibogaine analog.

Bretisilocin (GM-2505) is an investigational psychedelic compound in Phase 2 development for major depressive disorder (MDD). It acts as a short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser.

In a Phase 2a study, a single 10mg dose of bretisilocin demonstrated a significant reduction in depressive symptoms compared to a low-dose active comparator.

AbbVie aims to broaden and enhance psychiatric care by investing in novel treatment approaches for patients who have not responded to other treatments.

Do you think psychedelic therapies will become a mainstream treatment for mental health disorders? Let us know in the comments below!

Share this article with others who need to stay ahead of this trend!